Avalon GloboCare Corp. Annual Report - How They Did This Year

I’ve put together this guide to help you understand how Avalon GloboCare performed this year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Avalon GloboCare is shifting its business model. They are moving away from medical research to focus on two new areas:

• Consumer Health: They sell "Keto Air," a breathalyzer that tracks if your body is burning fat. Because it is a consumer product rather than a medical device, they avoid strict FDA approval requirements.
• Artificial Intelligence: Through their new subsidiary, RPM Interactive, they are building a platform. It uses generative AI to turn long podcasts into short social media clips featuring AI-generated avatars.

2. Major wins and challenges

• The Big Pivot: The company is cutting costs to save cash. They ended operations in China, exited a low-performing lab investment, and canceled a merger with YOOV Group to avoid integration costs and the need to issue more shares, which would have diluted existing shareholders.
• The AI Bet: In December 2025, they bought RPM Interactive for $19.5 million in stock. This is their "all-in" move to capture the creator economy. They are currently testing the platform and hope to reach influencers by late 2026.
• Lean Operations: As of March 2026, the company runs on just two full-time employees and a small group of contractors. This significantly lowers their monthly spending compared to their previous medical research team.

3. Financial health

This is the most concerning part of the report.

• Deep Losses: The company lost $17.5 million in 2025. This is a 150% increase in losses compared to the $7.0 million lost in 2024, largely due to acquisition costs.
• Going Concern: They have a total deficit of $105.9 million. Their auditors have issued a "going concern" warning, which signals significant doubt about the company’s ability to stay in business over the next year without finding more capital.
• No Revenue: The company reported almost no revenue for 2025. They are spending their remaining cash—less than $1.2 million at year-end—to build the RPM platform.

4. Key risks

• Survival Mode: With less than six months of cash left, the company must raise more money through debt or by issuing more shares. If they cannot secure funding, they face a high risk of insolvency.
• Regulatory Minefield: Their AI platform faces legal risks. They must navigate complex laws regarding the use of a person's likeness and strict AI transparency requirements in the EU and US.
• Competition: They are a tiny team competing against established giants like Adobe, Descript, and OpenAI. These competitors have significantly larger budgets and more advanced technology.

5. Future outlook

The company is betting everything on the RPM AI platform. Management states they need $3–5 million more to reach "meaningful revenue" by late 2026. To raise this, they are attempting to sell their remaining medical patents, though there is no guarantee a buyer will be found.

6. Competitive positioning

They aim to offer an "all-in-one" tool for creators. While this is designed to be simple to use, they currently lack a unique competitive advantage. Larger competitors could easily replicate their features and use their scale to price Avalon out of the market.

---

Investor Takeaway: Avalon GloboCare is currently a high-risk "turnaround" play. They have moved from medical research to the AI creator economy with very little cash on hand. Before considering an investment, weigh whether you believe their AI platform can generate revenue fast enough to overcome their significant debt and the "going concern" warning issued by their auditors.